S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
S&P 500   5,253.30 (+0.09%)
DOW   39,787.51 (+0.07%)
QQQ   443.86 (-0.22%)
AAPL   171.65 (-0.96%)
MSFT   420.44 (-0.23%)
META   488.15 (-1.16%)
GOOGL   150.88 (+0.01%)
AMZN   180.38 (+0.31%)
TSLA   176.84 (-1.66%)
NVDA   904.39 (+0.21%)
NIO   4.54 (-2.78%)
AMD   180.60 (+0.56%)
BABA   72.46 (+1.22%)
T   17.66 (+0.63%)
F   13.24 (+1.38%)
MU   117.64 (-1.26%)
CGC   9.13 (-4.40%)
GE   175.14 (-2.76%)
DIS   122.56 (+1.31%)
AMC   3.69 (-14.98%)
PFE   28.05 (+0.97%)
PYPL   67.24 (+1.01%)
XOM   116.14 (+1.02%)
NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Price, News & Analysis

$0.32
-0.05 (-13.51%)
(As of 02:09 PM ET)
Today's Range
$0.31
$0.41
50-Day Range
$0.33
$1.60
52-Week Range
$0.20
$12.15
Volume
245,420 shs
Average Volume
748,066 shs
Market Capitalization
$947,200.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Agile Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,444.9% Upside
$8.50 Price Target
Short Interest
Bearish
12.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.18mentions of Agile Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

AGRX stock logo

About Agile Therapeutics Stock (NASDAQ:AGRX)

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.

AGRX Stock Price History

AGRX Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Agile Therapeutics Announces Delisting from Nasdaq
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Agile Therapeutics's Earnings: A Preview
Agile Therapeutics reduces warrant exercise price
Why Is Agile Therapeutics (AGRX) Stock Up 87% Today?
Why Is Agile Therapeutics (AGRX) Stock Up 87% Today?
See More Headlines
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Confirmed)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+2,444.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-25,410,000.00
Pretax Margin
-69.73%

Debt

Sales & Book Value

Annual Sales
$10.88 million
Book Value
($6.83) per share

Miscellaneous

Free Float
2,949,000
Market Cap
$988,640.00
Optionable
Not Optionable
Beta
1.51
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Alfred F. AltomariMr. Alfred F. Altomari (Age 65)
    Chairman, President & CEO
    Comp: $644.4k
  • Mr. Geoffrey P. Gilmore (Age 58)
    Senior VP & Chief Administrative Officer
    Comp: $478.92k
  • Dr. Paul Korner M.B.A. (Age 58)
    M.D., Senior VP & Chief Medical Officer
    Comp: $480.4k
  • Mr. Scott M. Coiante (Age 57)
    CFO, Senior VP & Treasurer
    Comp: $520.45k
  • Matthew Riley
    Head of Investor Relations & Corporate Communications
  • Mr. Robert G. Conway M.E. (Age 66)
    Senior VP and Chief Corporate Planning & Supply Chain Officer
    Comp: $444.11k
  • Ms. Amy Welsh (Age 53)
    Senior VP & Chief Commercial Officer

AGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Agile Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AGRX shares.
View AGRX analyst ratings
or view top-rated stocks.

What is Agile Therapeutics' stock price target for 2024?

2 analysts have issued 12-month target prices for Agile Therapeutics' shares. Their AGRX share price targets range from $5.00 to $12.00. On average, they predict the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 2,444.9% from the stock's current price.
View analysts price targets for AGRX
or view top-rated stocks among Wall Street analysts.

How have AGRX shares performed in 2024?

Agile Therapeutics' stock was trading at $1.95 at the beginning of the year. Since then, AGRX shares have decreased by 82.9% and is now trading at $0.3340.
View the best growth stocks for 2024 here
.

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 361,300 shares, an increase of 62.7% from the February 29th total of 222,100 shares. Based on an average daily trading volume, of 698,200 shares, the short-interest ratio is currently 0.5 days. Currently, 12.7% of the shares of the stock are short sold.
View Agile Therapeutics' Short Interest
.

When is Agile Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our AGRX earnings forecast
.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.60) by $0.40. The specialty pharmaceutical company had revenue of $1.29 million for the quarter, compared to analysts' expectations of $1.49 million. During the same quarter in the prior year, the firm posted ($7.20) earnings per share.

When did Agile Therapeutics' stock split?

Shares of Agile Therapeutics reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (3.65%), Vanguard Group Inc. (0.69%), Vanguard Group Inc. (0.69%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred Altomari, Dennis Reilly, Jason Butch and Perceptive Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Agile Therapeutics?

Shares of AGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AGRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners